Figure 1
Figure 2
Figure 3
Patient and treatment characteristics
| Characteristics | Values |
|---|---|
| Gender | |
| Female | 38 (38%) |
| Male | 62 (62%) |
| Histological subtype | |
| Keratinizing | 2 (2%) |
| Non-keratinizing; differentiated | 32 (32%) |
| Non-keratinizing; undifferentiated | 66 (66%) |
| Stage | |
| II | 23 (23%) |
| III | 45 (45%) |
| IVA | 21 (21%) |
| IVB | 11 (11%) |
| T stage | |
| T1 | 28 (28%) |
| T2 | 30 (30%) |
| T3 | 20 (20%) |
| T4 | 22 (22%) |
| N stage | |
| N0 | 5 (5%) |
| N1 | 30 (30%) |
| N2 | 54 (54%) |
| N3a | 7 (7%) |
| N3b | 4 (4%) |
| Dose statistic | |
| D95% of PTV70, mean (SD) | 70.2 (0.5) |
| D95% of PTV59.4, mean (SD) | 59.8 (0.6) |
| D95% of PTV54, mean (SD) | 54.3 (0.8) |
| Conformity index (CI), mean (SD) | 0.89 (0.13) |
| Homogeneity index (HI), mean (SD) | 0.06 (0.07) |
| D2% of spinal cord, median (SD) | 34.1 (4.4) |
| D2 cc of brainstem, mean (SD) | 53.3 (6.3) |
| D50 of ipsilateral parotid gland, mean (SD) | 38.5 (11.2) |
| D50 of contralateral parotid gland, mean (SD) | 28.4 (6.7) |
Comparative studies of outcome and toxicities in NPC treated by HT concurrent with chemotherapy
| Study | Median Follow up (Range) (month) | No. of CCRT (%) | LRFFS (%) | DMFS (%) | OS (%) | Severe toxicity (grade > 2) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Acute Dermatitis (%) | Acute Mucositis (%) | Acute Pharyngitis (%) | Acute Xerostomia (%) | Late Xerostomia (%) | ||||||
| Wong et al. 22 | 34 (9-50) | 70 | 93.6 (3 yr) | 86.6 (3 yr) | 87.2 (3 yr) | - | 67.4 | - | - | 2.3 |
| Wolden et al. 23 | 35 (3-74) | 93 | 91 (3 yr) | 78 (3 yr) | - | - | - | - | - | - |
| Kam et al. 24 | 29 (8-45) | 30 | 92 (3 yr) | 79 (3 yr) | 90 (3 yr) | - | 92 | - | 75 | 23 (2 yr) |
| Lee et al. 7 | 31 (6-55) | 65 | 89.3 (2 yr) | 84.7 (2 yr) | 80.2 (2 yr) | - | 4.4 (grade4) | - | - | 3.1 |
| Tham et al. 25 | 36.5 | 100 | 93.1 (3 yr) | - | - | - | 29 | - | 3 | - |
| Lee et al. 26 | 31 (7-22) | 75 | 98 (4 yr) | 66 (4 yr) | 88 (4 yr) | - | 94 | - | - | 2.5 ( 2 yr) |
| Liu et al. 27 | 13 (8/18) | 58 | 100 (13 M) | - | - | 5 | 79 | - | 5 | - |
| Wang et al. 28 | 47.1 (11-68) | 83 | 94 (4 yr) | 85 (4 yr) | 86.1 (4 yr) | - | 33.3 | - | 4.7 | 12.3 (2 yr) |
| Sultanem et al. 27 | 21.8 (5-49) | 91 | 100 (4 yr) | 57 (4 yr) | 94 (4 yr) | - | 51 (grade3) | - | - | - |
| Du et al. 20 | 32 (3-38) | 64 | 96.1 (3 yr) | 92 (3 yr) | 86.3 (3 yr) | 4.7 | 3.2 | - | 0 | - |
| Leung et al. 17 | 41 (0.2-67) | 62.5 | 97 (5 yr) | 84.6 (5 yr) | - | 0 | 4 | - | - | 0 |
| Du et al. 21 | 23.7 (12-38) | 100 | 92.2 (2 yr) | 92.7 (2 yr) | 93.2 (2 yr) | 5.3 | 9.1 | 0.5 (grade 3) | 0 | - |
| Zhang et al. 30 | 48 (41.7-58) | 100 (cetuximab) | 95.2 (2 yr) | 88.1 (2 yr) | 93 (2 yr) | 7 (grade3) | 81.4 (grade3) | - | - | - |
| Our Study | 33 (25-41) | 100 | 94 (2 yr) | 96 (2 yr) | 99 (2 yr) | 5 | 37 (grade3) | 51 (grade 3) | - | 5 (grade 3) |